One of the greatest challenges in treating neurodegenerative diseases, such as Parkinson’s, is the effective delivery of therapeutic agents to the brain. Nutaria's proprietary intranasal nanotechnology overcomes the blood-brain barrier (BBB), allowing precise, targeted delivery of active ingredients directly to specific brain structures affected by the disease. This breakthrough approach ensures that therapeutic compounds reach areas most impacted by neurodegeneration, enabling a more effective treatment strategy. By targeting delivery, we offer a transformative step forward in modifying disease progression and improving patient outcomes.